Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD

Eye (Basingstoke)

Volumn 28, Issue 5, 2014, Pages 538-545

  Ehlken, C ^a   Jungmann, S ^a   Bohringer D ^a   Agostini, H T ^a   Junker, B ^a,b   Pielen, A ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MALE; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 84922391789     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2014.64     Document Type: Article

References (18)

1. Velez-Montoya R, Oliver SCN, Olson JL, Fine SL, Mandava N, Quiroz-Mercado H. Current knowledge and trends in age-related macular degeneration: todays and future treatments. Retina 2012; 33(8): 1487-1502
2. Schmidt-Erfurth U, Pollreisz A, Mitsch C, Bolz M. Antivascular Endothelial Growth Factors in Age-Related Macular Degeneration. In: Bandello F, Battaglia Parodi M, Augustin AJ, Iacono P, Schlingemann RO, Schmidt-Erfurth U (eds). Developments in Ophthalmology. KARGER: Basel, Switzerland, 2010, pp 21-38
3. Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 2008; 49(10): 4523-4527
4. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364(20): 1897-1908
5. CATT Research Group, Martin DF, Maguire MG, Fine SL, Ying G-S, Jaffe GJ et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119(7): 1388-1398
6. IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119(7): 1399-1411
7. Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology 2012; 119(5): 1001-1010
8. Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology 2012; 119(5): 992-1000
9. Dugel PU, Petrarca R, Bennett M, Barak A, Weinberger D, Nau J et al. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results. Ophthalmology 2012; 119(7): 1425-1431
10. Petrarca R, Dugel PU, Nau J, Slakter JS, Jaffe GJ, Jackson TL. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE Study): 12 month optical coherence tomography and fluorescein angiography. Ophthalmology 2012; 120(2): 328-333
11. Brown DM, Chen E, Mariani A, Major JC. Super-dose anti-VEGF (SAVE) trial: 2.0mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology 2012; 120(2): 349-354
12. Karagiannis DA, Ladas ID, Parikakis E, Georgalas I, Kotsolis A, Amariotakis G et al. Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe? Clin Interv Aging 2009; 4: 457-461
13. Stepien KE, Rosenfeld PJ, Puliafito CA, Feuer W, Shi W, Al-Attar L et al. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Retina 2009; 29(8): 1067-1073
14. Almony A, Mansouri A, Shah GK, Blinder KJ. Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab. Can J Ophthalmol 2011; 46(2): 182-185
15. Kumar N, Marsiglia M, Mrejen S, AT-C Fung, Slakter J, Sorenson J et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013; 33(8): 1605-1612
16. Gasperini JL, Fawzi AA, Khondkaryan A, Lam L, Chong LP, Eliott D et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 2012; 96(1): 14-20
17. Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol 2012; 96(1):
18. Abedi F, Wickremasinghe S, Richardson AJ, Makalic E, Schmidt DF, Sandhu SS et al. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology 2013; 120(1): 115-121.